## Soffia Gudbjornsdottir

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5546170/publications.pdf

Version: 2024-02-01

76 papers 6,056 citations

35 h-index 74163 75 g-index

77 all docs

77 docs citations

times ranked

77

8910 citing authors

#	Article	IF	Citations
1	Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2018, 379, 633-644.	27.0	888
2	Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine, 2017, 376, 1407-1418.	27.0	880
3	Type 1 diabetes mellitus. Nature Reviews Disease Primers, 2017, 3, 17016.	30.5	790
4	Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks. Circulation, 2019, 139, 2228-2237.	1.6	305
5	Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ: British Medical Journal, 2018, 363, k4365.	2.3	248
6	The National Diabetes Register in Sweden: An implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care, 2003, 26, 1270-1276.	8.6	199
7	Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study. BMJ, The, 2015, 350, h3234-h3234.	6.0	193
8	Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. Lancet Diabetes and Endocrinology,the, 2015, 3, 847-854.	11.4	144
9	Cancer incidence in persons with type $1$ diabetes: a five-country study of 9,000 cancers in type $1$ diabetic individuals. Diabetologia, 2016, 59, 980-988.	6.3	119
10	Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation, 2019, 139, 1900-1912.	1.6	108
11	Range of Risk Factor Levels. Circulation, 2017, 135, 1522-1531.	1.6	102
12	Association Between Socioeconomic Status and Mortality, Cardiovascular Disease, and Cancer in Patients With Type 2 Diabetes. JAMA Internal Medicine, 2016, 176, 1146.	5.1	100
13	Diabetes care – improvement through measurement. Diabetes Research and Clinical Practice, 2014, 106, S291-S294.	2.8	90
14	The Effect of Metformin and Insulin on Sympathetic Nerve Activity, Norepinephrine Spillover and Blood Pressure in Obese, Insulin Resistant, Normoglycemic, Hypertensive Men. Blood Pressure, 1994, 3, 394-403.	1.5	76
15	Long-term excess risk of heart failure in people with type $1$ diabetes: a prospective case-control study. Lancet Diabetes and Endocrinology,the, 2015, 3, 876-885.	11.4	69
16	Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ: British Medical Journal, 2019, 366, 14772.	2.3	69
17	Direct Measurements of the Permeability Surface Area for Insulin and Glucose in Human Skeletal Muscle. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4559-4564.	3.6	67
18	Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ, The, 2020, 369, m1186.	6.0	63

#	Article	IF	CITATIONS
19	Impact of Socioeconomic Status on Cardiovascular Disease and Mortality in 24,947 Individuals With Type 1 Diabetes. Diabetes Care, 2015, 38, 1518-1527.	8.6	61
20	What is important for you? A qualitative interview study of living with diabetes and experiences of diabetes care to establish a basis for a tailored Patient-Reported Outcome Measure for the Swedish National Diabetes Register. BMJ Open, 2016, 6, e010249.	1.9	58
21	Trends in blood pressure control in patients with type 2 diabetes – Data from the Swedish National Diabetes Register (NDR). Blood Pressure, 2011, 20, 348-354.	1.5	57
22	Short-term progression of cardiometabolic risk factors in relation to age at type 2 diabetes diagnosis: a longitudinal observational study of 100,606 individuals from the Swedish National Diabetes Register. Diabetologia, 2018, 61, 599-606.	6.3	57
23	Fructosamine Is a Useful Indicator of Hyperglycaemia and Glucose Control in Clinical and Epidemiological Studies – Cross-Sectional and Longitudinal Experience from the AMORIS Cohort. PLoS ONE, 2014, 9, e111463.	2.5	55
24	Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden. Lancet Diabetes and Endocrinology,the, 2019, 7, 106-114.	11.4	54
25	Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. Lancet Diabetes and Endocrinology,the, 2017, 5, 799-807.	11.4	53
26	Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study. BMJ, The, 2016, 354, i4070.	6.0	52
27	Decreased Muscle Capillary Permeability Surface Area in Type 2 Diabetic Subjects. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1078-1082.	3.6	50
28	Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes. Diabetes Care, 2016, 39, 996-1003.	8.6	50
29	Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. International Journal of Cancer, 2017, 140, 611-617.	5.1	47
30	The triglycerides-to-HDL-cholesterol ratio and cardiovascular disease risk in obese patients with type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR). Diabetes Research and Clinical Practice, 2014, 106, 136-144.	2.8	44
31	Cardiovascular safety of glucoseâ€lowering agents as addâ€on medication to metformin treatment in type 2 diabetes: report from the <scp>S</scp> wedish <scp>N</scp> ational <scp>D</scp> iabetes <scp>R</scp> egister. Diabetes, Obesity and Metabolism, 2016, 18, 990-998.	4.4	44
32	Renal and Cardiovascular Outcomes After Weight Loss From Gastric Bypass Surgery in Type 2 Diabetes: Cardiorenal Risk Reductions Exceed Atherosclerotic Benefits. Diabetes Care, 2020, 43, 1276-1284.	8.6	43
33	Glycaemic control and excess risk of major coronary events in persons with type 1 diabetes. Heart, 2017, 103, 1687-1695.	2.9	41
34	Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study. Diabetes Care, 2020, 43, 1326-1335.	8.6	41
35	Teenage girls with type 1 diabetes have poorer metabolic control than boys and face more complications in early adulthood. Journal of Diabetes and Its Complications, 2016, 30, 917-922.	2.3	39
36	Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes. Clinical Gastroenterology and Hepatology, 2019, 17, 2769-2775.e4.	4.4	37

#	Article	IF	Citations
37	Health-related quality of life and glycaemic control among adults with type 1 and type 2 diabetes $\hat{a} \in \hat{a}$ a nationwide cross-sectional study. Health and Quality of Life Outcomes, 2019, 17, 141.	2.4	36
38	Teenagers with poor metabolic control already have a higher risk of microvascular complications as young adults. Journal of Diabetes and Its Complications, 2016, 30, 533-536.	2.3	35
39	Excess risk of hospitalisation for heart failure among people with type 2 diabetes. Diabetologia, 2018, 61, 2300-2309.	6.3	31
40	A disease-specific questionnaire for measuring patient-reported outcomes and experiences in the Swedish National Diabetes Register: Development and evaluation of content validity, face validity, and test-retest reliability. Patient Education and Counseling, 2018, 101, 139-146.	2,2	30
41	Impact of ethnicity on progress of glycaemic control in 131 935 newly diagnosed patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. BMJ Open, 2015, 5, e007599-e007599.	1.9	29
42	Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR). Diabetologia, 2015, 58, 2259-2268.	6.3	28
43	International comparison of glycaemic control in people with type 1 diabetes: an update and extension. Diabetic Medicine, 2022, 39, e14766.	2.3	28
44	Co-aggregation and heritability of organ-specific autoimmunity: a population-based twin study. European Journal of Endocrinology, 2020, 182, 473-480.	3.7	27
45	Elevations of metabolic risk factors 20 years or more before diagnosis of type 2 diabetes: Experience from the AMORIS study. Diabetes, Obesity and Metabolism, 2018, 20, 1419-1426.	4.4	25
46	Pros and cons of gastric bypass surgery in individuals with obesity and type 2 diabetes: nationwide, matched, observational cohort study. BMJ Open, 2019, 9, e023882.	1.9	25
47	Mortality in patients with diabetes mellitus and Addison's disease: a nationwide, matched, observational cohort study. European Journal of Endocrinology, 2017, 176, 31-39.	3.7	23
48	Health Utilities of Type 2 Diabetes-Related Complications: A Cross-Sectional Study in Sweden. International Journal of Environmental Research and Public Health, 2014, 11, 4939-4952.	2.6	22
49	Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: Report from the Swedish National Diabetes Register. Diabetes and Vascular Disease Research, 2016, 13, 268-277.	2.0	22
50	Patient-reported outcome and experience measures for diabetes: development of scale models, differences between patient groups and relationships with cardiovascular and diabetes complication risk factors, in a combined registry and survey study in Sweden. BMJ Open, 2019, 9, e025033.	1.9	22
51	Development and validation of a cardiovascular risk prediction model in type 1 diabetes. Diabetologia, 2021, 64, 2001-2011.	6.3	22
52	PCI Versus CABG in Patients With TypeÂ1ÂDiabetesÂand Multivessel Disease. Journal of the American College of Cardiology, 2017, 70, 1441-1451.	2.8	21
53	Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study. BMJ Open, 2018, 8, e020309.	1.9	19
54	Comparison between data-driven clusters and models based on clinical features to predict outcomes in type 2 diabetes: nationwide observational study. Diabetologia, 2021, 64, 1973-1981.	6.3	19

#	Article	IF	CITATIONS
55	Durability of oral hypoglycemic agents in drug naÃ-ve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR). BMJ Open Diabetes Research and Care, 2015, 3, e000059.	2.8	17
56	The relationship between three eGFR formulas and hospitalization for heart failure in 54Â486 individuals with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2016, 32, 730-735.	4.0	17
57	Excess risk of lower extremity amputations in people with type 1 diabetes compared with the general population: amputations and type 1 diabetes. BMJ Open Diabetes Research and Care, 2019, 7, e000602.	2.8	17
58	Indications for Insulin Pump Therapy in Type 1 Diabetes and Associations With Glycemic Control. Journal of Diabetes Science and Technology, 2016, 10, 1027-1033.	2.2	15
59	Patients With Type 2 Diabetes Have an Increased Demand for Pacemaker Treatment: A Comparison With Age- and Sex-Matched Control Subjects From the General Population. Diabetes Care, 2020, 43, 2853-2858.	8.6	15
60	Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries. Diabetes Care, 2019, 42, e92-e94.	8.6	13
61	The comparative cardiovascular and renal effectiveness of sodiumâ€glucose coâ€transporterâ€2 inhibitors and glucagonâ€like peptideâ€l receptor agonists: A Scandinavian cohort study. Diabetes, Obesity and Metabolism, 2022, 24, 473-485.	4.4	13
62	Decreased eGFR as a Risk Factor for Heart Failure in 13 781 Individuals With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 131-136.	2.2	12
63	Excess Body Weight and Cancer Risk in Patients with Type 2 Diabetes Who Were Registered in Swedish National Diabetes Register – Register-Based Cohort Study in Sweden. PLoS ONE, 2014, 9, e105868.	2.5	11
64	Refill adherence and persistence to lipid-lowering medicines in patients with type 2 diabetes: A nation-wide register-based study. Pharmacoepidemiology and Drug Safety, 2017, 26, 1220-1232.	1.9	10
65	Changes in risk factors and their contribution to reduction of mortality risk following gastric bypass surgery among obese individuals with type 2 diabetes: a nationwide, matched, observational cohort study. BMJ Open Diabetes Research and Care, 2017, 5, e000386.	2.8	9
66	Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. Diabetologia, 2021, 64, 2204-2214.	6.3	9
67	Effect of Diabetes on Morbidity and Mortality in Patients With Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2483-2492.	3.6	8
68	Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type $1$ diabetes mellitus: a population-based study from the Swedish National Diabetes Register. BMJ Open Diabetes Research and Care, 2020, 8, e000719.	2.8	7
69	Glycaemic control and excess risk of major coronary events in patients with type 2 diabetes: a population-based study. Open Heart, 2019, 6, e000967.	2.3	5
70	Impact of Socioeconomic Factors and Gender on Refill Adherence and Persistence to Lipid-Lowering Therapy in Type 1 Diabetes. Diabetes Therapy, 2021, 12, 2371-2386.	2.5	5
71	Quality of life in chronic conditions using patient-reported measures and biomarkers: a DEA analysis in type $1$ diabetes. Health Economics Review, 2019, 9, 31.	2.0	4
72	New Diabetes Questionnaire to add patients' perspectives to diabetes care for adults with type 1 and type 2 diabetes: nationwide cross-sectional study of construct validity assessing associations with generic health-related quality of life and clinical variables. BMJ Open, 2020, 10, e038966.	1.9	4

#	Article	IF	CITATIONS
73	Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Bladder and Renal Cancer: Scandinavian Cohort Study. Diabetes Care, 2022, 45, e93-e96.	8.6	3
74	Decreased systolic blood pressure is associated with increased risk of all-cause mortality in patients with type 2 diabetes and renal impairment: A nationwide longitudinal observational study of 27,732 patients based on the Swedish National Diabetes Register. Diabetes and Vascular Disease Research, 2017, 14, 226-235.	2.0	2
75	Shared etiology of type 1 diabetes and Hashimoto's thyroiditis: a population-based twin study. European Journal of Endocrinology, 2022, 186, 677-685.	3.7	2
76	Electrical atrial vulnerability and renal complications in type 2 diabetes. Reply to Montaigne D, Coisne A, Sosner P et al [letter]. Diabetologia, 2016, 59, 863-864.	6.3	1